A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day on days 1, 2,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Petersdorf, Stephen H., Kopecky, Kenneth J., Slovak, Marilyn, Willman, Cheryl, Nevill, Thomas, Brandwein, Joseph, Larson, Richard A., Erba, Harry P., Stiff, Patrick J., Stuart, Robert K., Walter, Roland B., Tallman, Martin S., Stenke, Leif, Appelbaum, Frederick R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682338/
https://ncbi.nlm.nih.gov/pubmed/23591789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-466706
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados